Prelude Therapeutics price to book ratio PRLD

Market value divided by the book value of the company's net assets, since 2020.

Today, Oct 23, 2026: 2.2×
6-year median: 1.3×
Against its 6-year history: 69th; percentile: 0 is its lowest day, 100 its highest
6-year range: 0.3× to 17.0×
Peer median: 2.2×

Prelude Therapeutics' price to book ratio is 2.2× as of Oct 23, 2026.

That is above its 6-year median of 1.3×, higher than on 69% of days in the last 6 years.

Over that time it ranged from 0.3× in Mar 2025 to 17.0× in Feb 2021.

The median for 10 large drugmakers of a similar size is 2.2×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	2.2×	1.9×	6.5×
2025	2.6×	0.3×	2.6×
2024	0.5×	0.3×	1.6×
2023	1.0×	0.4×	2.0×
2022	1.3×	0.7×	1.7×
2021	1.9×	1.9×	17.0×
2020	13.7×	9.1×	17.0×

Against its peers

Companies in Drug Manufacturers - General nearest Prelude Therapeutics' size, closest first, today.

Company	Price to book ratio
PRLDPrelude Therapeutics	2.2×
NATRNatures Sunshine Products	1.3×
ARVNArvinas	0.8×
PBYIPuma Biotechnology	4.1×
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	2.7×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	2.4×
ABUSArbutus Biopharma	3.2×
AMPHAmphastar Pharmaceuticals	1.4×
LFVNLifevantage	2.2×
Peer median	2.2×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Prelude Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.